News and Insights | Lucid Group

Filter by type

All

Articles

Case Studies

News

White Papers

Filter by capability

All

Consulting

Scientific and Medical Communications

Commercial Communications

Group

Lucid Launches Lucid Group US: Fusing Science, Strategy, and Creative Storytelling to Accelerate Impact for Healthcare Brands

Image of the Lucid Group US exec team

Lucid Launches Lucid Group US: Fusing Science, Strategy, and Creative Storytelling to Accelerate Impact for Healthcare Brands

Lucid Group, a global leader in healthcare communications and commercialization, proudly announces the launch of Lucid Group US—a strategic unification of its US agencies, Lighthouse and DiD, under a single, integrated entity, representing a bold step forward in achieving Lucid’s mission of transforming lives.

View item

Reflections on the effectiveness of IEPs in 2025

Reflections

Reflections on the effectiveness of IEPs in 2025

The need for integrated evidence planning is well recognised across the industry. However, implementing the process and plan does not necessarily result in timely generation of high-quality evidence.

See article and view paper

Generative AI in development, medical and commercial: are our processes ready, and do we have the data?

Generative AI

Generative AI in development, medical and commercial: are our processes ready, and do we have the data?

There is opportunity as well as hype for generative AI in life sciences. Extensive value is not yet being realised in many areas.

See article and view paper

Reflections on iEGP

Reflections on integrated evidence generation planning

Reflections on iEGP

Delivering timely and robust evidence to external stakeholders is increasingly critical, as companies now face complex challenges in meeting the diverse...

See article and view paper

Harnessing AI to create economic and patient value

Harnessing AI to create economic and patient value

Harnessing AI to create economic and patient value

Across biopharma, many companies are jumping on the AI bandwagon in an effort to drive innovation and increase productivity. In a nascent, fast-moving...

See article and view paper

Data governance in a Zettabyte world: implications for R&D

Data Governance in a Zettabyte World

Data governance in a Zettabyte world: implications for R&D

In a world characterised by unprecedented generation, storage and utilisation of data on a massive scale, the biopharmaceutical industry has been compelled...

See article and view paper

Future of Regulatory Affairs

The Future of Regulatory Affairs

Future of Regulatory Affairs

We present a series of opportunities and challenges for biopharmaceutical Regulatory Affairs. Underpinning the preparations and response is the need...

See article and view paper

Digitisation in Medical Affairs

Digitisation and AI in Medical Affairs

Digitisation in Medical Affairs

Artificial intelligence (AI) and broader digitisation are now key areas of focus and investment for many biopharma companies. While use cases have been...

See article and view paper

Optimising external engagement in the digital age

Optimising External Engagement in the Digital Age

Optimising external engagement in the digital age

Technological developments and the ever-increasing breadth and depth of new information and evidence being generated have driven many life sciences...

See article and view paper

GCP impact on clinical operations

ICH GCP E6 R3: Impact on Clinical Operations

GCP impact on clinical operations

We present an expert-backed view on the revision to Good Clinical Practice (ICH GCP E6 R3) and the likely impact of these changes on clinical operations.

See article and view paper

EU Clinical Trial Regulation: sponsor preparedness

EU Clinical Trial Regulation

EU Clinical Trial Regulation: sponsor preparedness

January 2022 was the 'Go-Live' for the EU Clinical Trial Regulation and CTIS. Steve Gunnigle shares some insights.

See article and view paper

Outsourcing strategy for scalable growth

Outsourcing strategy for Scalable Growth

Outsourcing strategy for scalable growth

Target Clinical Development outsourcing operating model.

See case study

Digitising Medical planning

Digitizing Medical Planning

Digitising Medical planning

Digitising of Global oncology Medical strategy plans across assets.

See case study

Medical Affairs KPIs

Medical Affairs KPIs

Medical Affairs KPIs

The purpose of this paper is to describe how effective Medical Affairs KPIs can be developed as straightforwardly as possible, and to present key elements that organisations should consider in their own KPI dashboards.

See article and view paper

Medical operations of the future

Banner image introducing Medical Operations of the Future

Medical operations of the future

As Medical Affairs organisations continue to evolve, the 'Medical Operations' or 'Medical Excellence' group is becoming increasingly important. This paper explores how Medical Operations groups can best evolve to...

See article and view paper

DCTs: achieving our ambition

Banner image introducing Decentralised Clinical Trials: Achieving Our Ambition?

DCTs: achieving our ambition

Decentralised clinical trials (DCTs) present a biopharmaceutical company with a series of opportunities and challenges. We highlight the challenges and examine...

See article and view paper

Accelerating the pathway to launch for a breakthrough oncology asset

Cross-functional launch readiness in oncology

Accelerating the pathway to launch for a breakthrough oncology asset

Our client needed a partner to help them navigate the journey to launch and successfully bring their product to market while creating a model for future launches across the organisation.

See case study

Data Strategy: The Importance of Looking Forward, not just measuring the past

Data Strategy

Data Strategy: The Importance of Looking Forward, not just measuring the past

View article

Everyone deserves better health

Disparities in care image

Everyone deserves better health

Learn how we used our proprietary advanced analytics, hyper-targeted media, and digital efforts to help a P2-positioned brand achieve a 30% increase in NRx and a 10-point gain in market share.

See case study

Insights: The heart of creative problem solving

Insights

Insights: The heart of creative problem solving

View article

It's time to start taking things non-personally

Transforming untapped potential image

It's time to start taking things non-personally

Learn how we used our proprietary advanced analytics, hyper-targeted media and digital efforts to help a P2-positioned brand achieve a 30% increase in NRx and a 10-point gain in market share.

See case study

Let's do launch

Transforming a delayed market entry image

Let's do launch

Learn how we used data-driven intelligence and strategic scenario planning to deliver a flawless launch for a new biologic, transitioning our client from peripheral player to category leader.

See case study

Does your brand need another bounce?

Transforming a steady decline image

Does your brand need another bounce?

Learn how we used advanced analytics and relevant insight to lift a steadily declining legacy brand to its highest growth rate in NBRx share in 5 years.

See case study

Had enough media mediocrity?

Transforming strong headwinds image

Had enough media mediocrity?

Learn how we used advanced analytics to find insights that dramatically increased a client’s campaign performance and increased ROI 7:1.

See case study

Our transformation journey—where we’ve been and where we’re going

Our transformation journey

Our transformation journey—where we’ve been and where we’re going

View item

Dramatically improving audience quality and campaign ROI with LCI targeting data overlays

Dramatically improving audience quality image

Dramatically improving audience quality and campaign ROI with LCI targeting data overlays

MAVENCLAD (cladribine) positions itself as the oral of choice for first switch in active RMS.

See case study

Infusing innovation with emotion to launch a one-of-a-kind product

Infusing innovation with emotion image

Infusing innovation with emotion to launch a one-of-a-kind product

Naloxone was being launched as a branded product in a complex generic market.

See case study

Expanding the brand footprint into paid social

Expanding the brand footprint into paid social

MAVENCLAD (cladribine) needed to find a way to stand out from the competition and expand paid social presence beyond Facebook and Instagram.

See case study

Challenging engrained treatment behaviours: Disrupt the Decline

Challenging engrained treatment behaviors image

Challenging engrained treatment behaviours: Disrupt the Decline

Despite clinical acceptance of the efficacy of long-acting injectables (LAIs) to provide prolonged stability for people suffering from schizophrenia, they still only make up about 13% of the market.

See case study

Lucid Group receives EcoVadis certification

Lucid Group receives EcoVadis certification

Lucid Group receives EcoVadis certification

View item

Lucid Spirit programme

Lucid Spirit programme

Lucid Spirit programme

View item

Lucid Group is officially a member of the United Nations Global Compact

Lucid Group is officially a member of the United Nations Global Compact

Lucid Group is officially a member of the United Nations Global Compact

View item

Real-world data fueled media: Finding and exploiting the subtle factors that influence clinical decision-making

Real-world data fueled media

Real-world data fueled media: Finding and exploiting the subtle factors that influence clinical decision-making

View article

Clinical insights and implications from DDW

Clinical insights

Clinical insights and implications from DDW

View article

You are what you treat: Medical specialty choices, personalities, and perspectives

You are what you treat

You are what you treat: Medical specialty choices, personalities, and perspectives

View article

Swiftly and purposefully establishing a meaningful connection with healthcare professionals (HCPs), patients, payers, influencers, and stakeholders

Swiftly and purposefully establishing

Swiftly and purposefully establishing a meaningful connection with healthcare professionals (HCPs), patients, payers, influencers, and stakeholders

View article

Lucid Group acquires leading consulting firm Synetic Life Sciences

Lucid Group acquires leading consulting firm Synetic Life Sciences

Lucid Group acquires leading consulting firm Synetic Life Sciences

View item

Celebrating pioneers in healthcare and society

Celebrating pioneers in healthcare and society

Celebrating pioneers in healthcare and society

View item

Listen, learn and lift off

Listen, learn and lift off

Listen, learn and lift off

View item

Launch excellence

Launch excellence

Launch excellence

View article

Extraordinary lives: Advancing change in rare diseases (Part 2)

Extraordinary lives

Extraordinary lives: Advancing change in rare diseases (Part 2)

View article

Extraordinary lives: Advancing change in rare diseases

Extraordinary lives

Extraordinary lives: Advancing change in rare diseases

View article

Making way for a new brand

Making way for a new brand

Learn how an award-winning omnichannel programme challenged the status quo, drove a paradigm shift, and boosted early sales.

See case study

Pipeline prioritisation, positioning and planning

Pipeline prioritisation, positioning and planning

Pipeline prioritisation, positioning and planning

A robust, cross-functional approach to set the strategic direction for pipeline assets and their target indications in the context of an existing portfolio.

See case study

Minding the gaps

minding the gaps

Minding the gaps

Learn how gathering internal and external community insights transformed an integrated evidence-generation plan and maximised product differentiation opportunities ahead of launch.

See case study

Portfolio buy and build

Portfolio buy and build

Portfolio buy and build

A thorough process to assess and validate future development and acquisition targets, optimising portfolio and disease area strategy and aligning key stakeholders to plan.

See case study

Animated back to basics

Animated back to basics

Animated back to basics

Learn how a highly visual animation used a novel analogy to break down and explain the science behind the disease, ensuring a wide audience base can understand the value of a new treatment.

See case study

Readying the community for change

Readying the community for change

Readying the community for change

Learn how a multi-interventional educational campaign elevated the standard of care and prepared the clinical and patient community for a new treatment option.

See case study

Making it happen where you are

Making it happen where you are

Making it happen where you are

Learn how a global educational programme can be successfully activated in local markets through targeted engagement, insight-driven planning and some healthy in-team competition.

See case study

Building a community and a reputation

Building a community and a reputation

Building a community and a reputation

Learn how an award-winning scientific exchange programme keeps a clinical community up to date with advances in the therapy area, while also elevating standards of care and building our client’s reputation.

See case study

Global evidence generation strategy

Global evidence generation strategy

Global evidence generation strategy

Development of an evidence-generation strategy and expanded LCM opportunities to drive competitive differentiation aligned to stakeholder market-value drivers.

See case study

Sorry we couldn’t find any matches for your current filters.

Try broadening your search or exploring a different combination.

Are you ready to transform the potential of your asset or brand?